Vasculitides associated with malignancies: Analysis of sixty patients
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To describe characteristics and outcomes of vasculitides associated with malignancies. Methods: The requirement for inclusion in this retrospective, 10‐year study was development of vasculitis in patients with a progressing malignancy. Malignancies secondary to immunosuppressants used to treat vasculitis were excluded. The main characteristics of vasculitides were analyzed and compared according to the type of malignancy. Results: Sixty patients were included (male/female sex ratio 2.53, mean age 62.4 years). Mean followup duration was 45.2 months. Vasculitides were cutaneous leukocytoclastic (45%), polyarteritis nodosa (36.7%), Wegener's granulomatosis (6.7%), microscopic polyangiitis (5%), and Henoch‐Schönlein purpura (5%). Malignancies were distributed as follows: hematologic in 63.1%, myelodysplastic syndrome (MDS) in 32.3%, lymphoid in 29.2%, and solid tumor in 36.9%. Vasculitides were diagnosed concurrently with malignancy in 38% of the cases. Manifestations of vasculitides were fever (41.7%), cutaneous involvement (78.3%), arthralgias (46.7%), peripheral neuropathy (31.7%), renal involvement (23.3%; 11.7% glomerulonephritis, 11.7% microaneurysms, 6.7% renal insufficiency), and antineutrophil cytoplasmic antibody (20.4%). Vasculitis treatments were corticosteroids (78.3%) and immunosuppressant(s) (41.7%). Vasculitis was cured in 65% of patients, but 58.3% died, with 1 death secondary to vasculitis. Independent of subtype, patients with vasculitides associated with MDS more frequently had renal manifestations (P = 0.02) and steroid dependence (P = 0.04) and achieved complete remission less often (P = 0.04) than patients with vasculitides associated with other malignancies. Patients with vasculitides associated with a solid tumor more frequently had peripheral neurologic involvement (P = 0.05). Patients with vasculitides associated with lymphoid malignancy had less frequent arthralgias (P = 0.01) and renal involvement (P = 0.02). Conclusion: Vasculitides occurring during malignancies present distinctive features according to the vasculitis subtype and nature of the malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
What is known about the epidemiology of the vasculitides?
Watts, R. A., Lane, S., & Scott, D. G. I. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.11.006 · Cited by 178
Malignancy is increased in ANCA-associated vasculitis
Pankhurst, T. (2004) · Rheumatology · doi:10.1093/rheumatology/keh374 · Cited by 172
Blanco, R., Martinez-Taboada, V. M., Rodriguez-Valverde, V., & Garcia-Fuentes, M. (1998) · Medicine · doi:10.1097/00005792-199811000-00007 · Cited by 172
Vasculitides in hairy cell leukemia
Hasler, P., Hj, K., & Gerber, H. (1995) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(95)80026-3 · Cited by 135
Wegener's granulomatosis associated with renal cell carcinoma
Tatsis, E., Reinhold‐Keller, E., Steindorf, K., Feller, A. C., & Gross, W. L. (1999) · Arthritis & Rheumatism · Cited by 134
Adult Henoch-Schönlein purpura associated with malignancy
Pertuiset, É., Lioté, F., Russ, E., Kemiche, F., Cerf-Payrastre, I., & Chesneau, A. M. (2000) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2000.6988 · Cited by 110
Temporal concurrence of vasculitis and cancer: A report of 12 cases
Hutson, T. E., & Hoffman, G. S. (2000) · Arthritis & Rheumatism · Cited by 97
Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia
Hamidou, M. A., Boumalassa, A., Larroche, C., Kouri, D. E., Blétry, O., & Grolleau, J. (2001) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2001.27717 · Cited by 78
Self-citationRenal Cell Carcinoma and Paraneoplastic IgA Nephropathy
Magyarlaki, T., Kiss, B., Buzogány, I., Fazekas, A., Sükösd, F., & Nagy, J. (1999) · The Nephron journals/Nephron journals · doi:10.1159/000045388 · Cited by 60
Cited by
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., & Garcia-Manero, G. (2015) · Leukemia · doi:10.1038/leu.2015.69 · Cited by 236
Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations
Koike, H., Tanaka, F., & Sobue, G. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834a87b7 · Cited by 105
Autoimmunity and Inflammation in Myelodysplastic Syndromes
Wolach, O., & Stone, R. (2016) · Acta Haematologica · doi:10.1159/000446062 · Cited by 51
Metadata
- Authors
- Fain, O., Hamidou, M., Cacoub, P., Godeau, B., Wechsler, B., ParIès, J., Stirnemann, J., Morin, A., Gatfosse, M., Hanslik, T., Belmatoug, N., Blétry, O., Cevallos, R., Delevaux, I., Fisher, E., Hayem, G., Kaplan, G., Le hello, C., Mouthon, L., Larroche, C., Lemaire, V., Piette, A., Piette, J., Ponge, T., Puechal, X., Rossert, J., Sarrot‐Reynauld, F., Sicard, D., Ziza, J., Kahn, M., & Guillevin, L.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2007-11-29
- Volume
- 57
- Issue
- 8
- Pages
- 1473-1480
- ISSN
- 0893-7524 (ISSN-L)
- 1529-0123
- OpenAlex
- W2025608060
- Cited by
- 300
- References
- 10
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vasculitides associated with malignancies: Analysis of sixty patients. https://app.cochat.ai/papers/10.1002/art.23085
- The paper
- Fain, O., Hamidou, M., Cacoub, P., Godeau, B., Wechsler, B., ParIès, J., Stirnemann, J., Morin, A., Gatfosse, M., Hanslik, T., Belmatoug, N., Blétry, O., Cevallos, R., Delevaux, I., Fisher, E., Hayem, G., Kaplan, G., Le hello, C., Mouthon, L., . . . Guillevin, L. (2007). Vasculitides associated with malignancies: Analysis of sixty patients. Arthritis Care & Research. https://doi.org/10.1002/art.23085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.